FIELD: medicine, pharmaceutics.SUBSTANCE: invention related to a spiro amino compound of formula,wherein m represents 1 or 2 or 3, n represents 1 or 2, R is specified in a 6-merous aromatic ring and a 5-merous heteroaromatic ring containing 1 to 2 heteroatoms specified in S and N this ring is substituted by one or two substitutes specified in a group consisting of (C1-C3)alkyl, halogen atom, (C3-C5)cycloalkyloxygroup, phenyl optionally substituted by one or more halogen atoms, 5- or 6-merous heterocycle containing at least one nitrogen atom specified in 1,2,3-triazole, pyrimidine, pyridine, and pyrazine P represents a substitute Q, wherein Q is specified in a group consisting of phenyl, pyridyl, pyrimidyl Q is optionally substituted by one or more substitutes specified in a group consisting of (C1-C3)alkyl, halogen, trifluoromethyl, methylcarboxygroup. The invention also refers to a spiro amino compound of formula (VI), wherein m represents 1 or 3, n represents 1 or 2, R represents phenyl substituted by the substitute cyclopropyl (C1-C3)alkoxy, P represents a substitute Q, wherein Q is specified in a group consisting of phenyl, pyridyl, pyrimidinyl Q is optionally substituted by one or more substitutes specified in a group consisting of (C1-C3)alkyl, halogen, trifluoromethyl and methylcarboxygroup. The compounds of formula IV are applicable to produce a drug preparation for treating the pathologies, which require an orexin receptor 1 antagonist to be applied.EFFECT: spiro amino compounds possessing the orexin receptor agonist activity.19 cl, 99 exИзобретение имеет отношение к спиро-аминосоединению формулы (VI), где m представляет собой 1 или 2 или 3, n представляет собой 1 или 2, R выбирают из 6-членного ароматического кольца и 5-членного гетероароматического кольца, содержащего от 1 до 2 гетероатомов, выбранных из S и N, причем такое кольцо является замещенным одним или двумя заместителями, выбранными из группы, состоящей из (С1-С3)алкила, атома галогена, (С3-С5)ци
